Trial
NCT03625687
Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Massachusetts General Hospital
Collaborators
—
Condition
Respiratory Failure
Intervention
Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks
Why stopped
Lack of funding, transitioned to standard of care
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-25